IRVINE, Calif., June 30, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that the company's management team will participate at the SVB Securities Therapeutics Forum.

SVB Securities Therapeutics Forum

Date: Tuesday, July 11th – Wednesday, July 12th, 2023

Location: The Lotte Palace, New York, N.Y.

About Reneo Pharmaceuticals

Reneo is a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Our lead product candidate, mavodelpar (REN001), is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ). Mavodelpar has been shown to increase transcription of genes involved in mitochondrial function, increase fatty acid oxidation, and may increase production of new mitochondria. For additional information, please see reneopharma.com.

Contacts:

Danielle Spangler 

Investor Relations 

Reneo Pharmaceuticals, Inc. 

dspangler@reneopharma.com

Matthew Purcell, Pharm.D.

Media Inquiries 

Russo Partners, LLC 

matthew.purcell@russopartnersllc.com